大洋洲 · 新闻 · The Mercury

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

来源：The Mercury · 澳大利亚 12 小时前

Alterity Therapeutics has presented additional analyses of its Phase 2 trial showing the 50mg twice-daily dose of its lead drug candidate ATH434 slowed functional ...

在 The Mercury 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.themercury.com.au)

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

推荐阅读

Major parties all flag big cuts to immigration numbers

Behind the scenes at Perth’s most controversial expo

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

A family's heartbreak after watching a loved one die from Australia's no.1 killer

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

分享

推荐阅读

Major parties all flag big cuts to immigration numbers

Behind the scenes at Perth’s most controversial expo

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

A family's heartbreak after watching a loved one die from Australia's no.1 killer

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’